History & Mission

Home About Monteris History & Mission

Pioneering Minimally Invasive Laser Ablation Systems

Monteris Medical was founded in 1999 with the sole focus to help patients suffering from neurological diseases. The company’s goal remains: to create a minimally invasive surgical option for use in the brain.

Monteris and its employees are dedicated to improving the lives of patients, and the people around them, all of whom are affected by epilepsy or brain tumors. We come to work every day committed to developing and delivering leading-edge neurosurgical technology – work that is founded in science and supported by evidence – to enable the safe use of our minimally invasive technology.Martin J. Emerson

Guiding Principles

Our mission is to be the leader in image-guided thermal therapy, providing proven, intuitive and integrated solutions that deliver value to our partners in the treatment of epilepsy and brain cancer.

We offer hope and healing to patients world-wide as the partner of choice in delivering transformative neurological solutions.

Monteris Medical is committed to delivering innovative neurological solutions by:

  • Establishing appropriate requirements from a comprehensive understanding of our users and regulations in applicable geographies.
  • Ensuring our products, processes, and services meet their requirements.
  • Using data and feedback to drive continuous improvement to ensure the effectiveness of our Quality Management System.

NeuroBlate® System Timeline

March 2020


  • 3,000 Patient Milestone Achieved
  • Launched NeuroBlate Fusion-S Software with 3-D Anatomical Views
  • Monteris Founders, Dr. Mark Torchia and Richard Tyc Receive the Pioneer in Technology Award by The Society for Brain Mapping & Therapeutics
  • 12- Month Results of LAANTERN (Laser Ablation of Abnormal Neurological TissuE using Robotic NeuroBlate System) Published in Neurosurgery 

March 2019


  • 2,500 Patient Milestone Achieved
  • 500th Patient Enrolled in LAANTERN (Laser Ablation of Abnormal Neurological TissuE using Robotic NeuroBlate System) Study

March 2018


  • Launched NeuroBlate Optic™ Laser Probe
  • 2,000 Patient Milestone Achieved
  • LAASR (Laser Ablation After Stereotactic Radiosurgery) Results published in the Journal of Neurosurgery

March 2017


Launched NeuroBlate Fusion™ Software with advanced image co-registration tools and enhanced visualization of the ablation target

March 2016


Launched M*Vision Pro Software™

Dr. Mark Torchia and Richard Tyc receive Governor General of Canada Innovation Award for the NeuroBlate System

March 2015



  • FullFire® Select Mini Probes
  • NeuroBlate Robotic Probe Driver Mini-Bolt 2.2
  • Mini-Bolt Access Tool Kit

Voted Gold Winner of Medical Device Excellence Award

Dr. Mark Torchia and Richard Tyc receive Principle Innovation Award for the NeuroBlate System (Ernest C. Manning Foundation)

March 2014



  • AtamA Patient Board 3T
  • Philips MRI Interface
  • Mini-Bolt Access
  • NeuroBlate Robotic Probe Driver

NeuroBlate System commercially available in Canada

March 2013



  • NeuroBlate System for 1.5T and 3T MRI
  • Advanced Probe Driver (Robotic LITT)
  • M*Vision Software™
  • FullFire® Probe
  • GE MRI Interface

March 2012


Moved Headquarters to Minneapolis, Minnesota, USA

March 2011


Launched AtamA™ Patient Board

March 2010


First commercial use of AutoLITT® (now NeuroBlate System) with Sidefire® Probe on 1.5T MRI

March 2009


FIM Trial completed, 10 patients at Cleveland Clinic and University Hospital Case Medical Center

AutoLITT (now the NeuroBlate System) and AXiiiS® Stereotactic Miniframe launched and commercially available in the United States

March 2008


First-in-Man (FIM) Safety Trial begins with AutoLITT “Gen1” system

March 2005


Delivered clinical proof of prototype with in-vivo test

March 1999


Final bench model developed

AutoLITT, Ltd. is founded in Canada (later renamed to Monteris Medical in 2003).

March 1992


First prototype of device built by Dr. Mark Torchia in Winnipeg, Canada